In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

Samankaltaisia teoksia

• Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
  Tekijä: Thadepalli, H, et al.
  Julkaistu: (1986)
• Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis.
  Tekijä: Gollapudi, S V, et al.
  Julkaistu: (1988)
• Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.
  Tekijä: Thadepalli, H, et al.
  Julkaistu: (1997)
• In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
  Tekijä: Girard, A E, et al.
  Julkaistu: (1995)
• In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.
  Tekijä: Gollapudi, S V, et al.
  Julkaistu: (1993)